Women’s Experiences With Isotretinoin Risk Reduction Counseling | Acne | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.
1.
Williams  HC, Dellavalle  RP, Garner  S.  Acne vulgaris.  Lancet. 2012;379(9813):361-372.PubMedGoogle ScholarCrossref
2.
Picardi  A, Lega  I, Tarolla  E.  Suicide risk in skin disorders.  Clin Dermatol. 2013;31(1):47-56.PubMedGoogle ScholarCrossref
3.
Layton  A.  The use of isotretinoin in acne.  Dermatoendocrinol. 2009;1(3):162-169.PubMedGoogle ScholarCrossref
4.
Saitta  P, Grekin  SK.  A four-question approach to determining the impact of acne treatment on quality of life.  J Clin Aesthet Dermatol. 2012;5(3):51-57.PubMedGoogle Scholar
5.
Cyrulnik  AA, Viola  KV, Gewirtzman  AJ, Cohen  SR.  High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life.  Int J Dermatol. 2012;51(9):1123-1130.PubMedGoogle ScholarCrossref
6.
Honein  MA, Lindstrom  JA, Kweder  SL.  Can we ensure the safe use of known human teratogens? the iPLEDGE test case.  Drug Saf. 2007;30(1):5-15.PubMedGoogle ScholarCrossref
7.
Maloney  ME, Stone  SP.  Isotretinoin and iPLEDGE: a view of results.  J Am Acad Dermatol. 2011;65(2):418-419.PubMedGoogle ScholarCrossref
8.
Brinker  A, Kornegay  C, Nourjah  P.  Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the Accutane SMART program.  Arch Dermatol. 2005;141(5):563-569.PubMedGoogle ScholarCrossref
9.
Bérard  A, Azoulay  L, Koren  G, Blais  L, Perreault  S, Oraichi  D.  Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective.  Br J Clin Pharmacol. 2007;63(2):196-205.PubMedGoogle ScholarCrossref
10.
Shin  J, Cheetham  TC, Wong  L,  et al.  The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system.  J Am Acad Dermatol. 2011;65(6):1117-1125.PubMedGoogle ScholarCrossref
11.
Food and Drug Administration.  Briefing document for iPLEDGE year one update: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4311b1-02-ipledge.pdf . updated February 28, 2007. Accessed September 20, 2012.
12.
Crijns  I, Straus  S, Luteijn  M, Gispen-de Wied  C, Raine  J, de Jong-van den Berg  L.  Implementation of the harmonized EU isotretinoin Pregnancy Prevention Programme: a questionnaire survey among European regulatory agencies.  Drug Saf. 2012;35(1):27-32.PubMedGoogle ScholarCrossref
13.
Schaefer  C, Meister  R, Weber-Schoendorfer  C.  Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy.  Arch Gynecol Obstet. 2010;281(2):221-227.PubMedGoogle ScholarCrossref
14.
Winner  B, Peipert  JF, Zhao  Q,  et al.  Effectiveness of long-acting reversible contraception.  N Engl J Med. 2012;366(21):1998-2007.PubMedGoogle ScholarCrossref
Original Investigation
April 2014

Women’s Experiences With Isotretinoin Risk Reduction Counseling

Author Affiliations
  • 1School of Medicine, University of Pittsburgh, Pittsbugh, Pennsylvania
  • 2Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
  • 3Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania
  • 4Department of Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, Pennsylvania
  • 5Women’s Health Services Research Unit, Center for Research on Health Care, University of Pittsburgh, Pittsburgh, Pennsylvania
JAMA Dermatol. 2014;150(4):366-371. doi:10.1001/jamadermatol.2013.6862
Abstract

Importance  Isotretinoin, an effective anti-acne therapy, is a known teratogen that is strictly regulated through the iPLEDGE program. However, since this program has not significantly reduced rates of pregnancies exposed to isotretinoin, new strategies for reducing rates of isotretinoin-exposed pregnancies are needed.

Objective  To explore women’s experiences with counseling about isotretinoin risk reduction.

Design, Setting, and Participants  Structured interviews were conducted between January and September 2012. Two independent coders performed content analysis using a grounded theory approach. The study participants were 16 women who had used isotretinoin to treat severe skin disease and who were recruited from a single urban community via flyers displayed on college campuses, at dermatology clinics, and at student health facilities.

Main Outcomes and Measures  Perceptions of isotretinoin-associated risks and understanding of ways teratogenic risks can be avoided.

Results  Participants clearly understood that isotretinoin is teratogenic but had less understanding of contraceptive methods that effectively prevent pregnancy. Most described the counseling they received as anxiety provoking. Few were counseled about highly effective reversible contraceptives such as the subdermal implant or intrauterine contraception; most counseling focused on oral contraceptives. Women cited multiple influences on their contraceptive choices, including friends, family, physicians, the internet, and other media; however, some expressed concerns about the accuracy of these sources of information. For many, iPLEDGE was their first introduction to contraception. When presented with evidence-based information on the relative effectiveness of available contraceptives, participants expressed surprise that this was not part of the iPLEDGE materials.

Conclusions and Relevance  Since few clinicians provide women information on highly effective (ie, intrauterine or subdermal) contraceptives, the iPLEDGE program increases anxiety about isotretinoin more than it helps women feel protected from the teratogenic risks of isotretinoin.

×